Abstract
Randomized, controlled trial results have shown dronedarone, an amiodarone analogue, to be superior to placebo in reducing atrial fibrillation (JW Cardiol Sep 5 2007). However, findings of increased mortality with dronedarone in heart failure patients have raised concerns (JW Cardiol Jun 18 2008). Therefore, these results from ATHENA, an international study sponsored and administered by dronedarone’s manufacturer, have been eagerly anticipated. Eligible patients had AF and at least one of the following conditions: hypertension, diabetes, previous stroke or transient ischemic attack, left atrial enlargement, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
